Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Moschos

Showing results (41-50 of 88) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Next generation of immunotherapy for melanomaJohn M Kirkwood, Ahmad A Tarhini, Monica C Panelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanomaAhmad A Tarhini, John Cherian, Stergios J Moschos, et al.
The Journal of Clinical Endocrinology and Metabolism|December 23, 2004
Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiencyJean L Chan, Stergios J Moschos, John Bullen, et al.
Annals of Surgical Oncology|June 26, 2026
Implementing Paradigm Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma PatientsKristen E Dougherty, Gray B Peery, Ananya Saravanan, et al.
Journal of Computer Assisted Tomography|September 17, 2016
Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and MelanomaAna Marija Franceschi, Stergios J Moschos, Carey K Anders, et al.
Melanoma Research|May 17, 2007
Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agentsStergios J Moschos, Christine Odoux, Stephanie R Land, et al.
Annals of Surgical Oncology|July 3, 2026
ASO Visual Abstract: Implementing Paradigm-Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma PatientsKristen E Dougherty, Gray B Peery, Ananya Saravanan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696John M Kirkwood, Sandra Lee, Stergios J Moschos, et al.
NPJ Genomic Medicine|August 17, 2021
Multiregional genetic evolution of metastatic uveal melanomaDaniel A Rodriguez, Jessica Yang, Michael A Durante, et al.
Melanoma Research|May 11, 2017
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanomaAhmad A Tarhini, Stergios J Moschos, Yan Lin, et al.
Pageof 9

Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Next generation of immunotherapy for melanomaJohn M Kirkwood, Ahmad A Tarhini, Monica C Panelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanomaAhmad A Tarhini, John Cherian, Stergios J Moschos, et al.
The Journal of Clinical Endocrinology and Metabolism|December 23, 2004
Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiencyJean L Chan, Stergios J Moschos, John Bullen, et al.
Annals of Surgical Oncology|June 26, 2026
Implementing Paradigm Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma PatientsKristen E Dougherty, Gray B Peery, Ananya Saravanan, et al.
Journal of Computer Assisted Tomography|September 17, 2016
Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and MelanomaAna Marija Franceschi, Stergios J Moschos, Carey K Anders, et al.
Melanoma Research|May 17, 2007
Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agentsStergios J Moschos, Christine Odoux, Stephanie R Land, et al.
Annals of Surgical Oncology|July 3, 2026
ASO Visual Abstract: Implementing Paradigm-Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma PatientsKristen E Dougherty, Gray B Peery, Ananya Saravanan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696John M Kirkwood, Sandra Lee, Stergios J Moschos, et al.
NPJ Genomic Medicine|August 17, 2021
Multiregional genetic evolution of metastatic uveal melanomaDaniel A Rodriguez, Jessica Yang, Michael A Durante, et al.
Melanoma Research|May 11, 2017
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanomaAhmad A Tarhini, Stergios J Moschos, Yan Lin, et al.
Pageof 9